Cupriavidus gilardii is a rare environmental gram-negative bacillus that has been increasingly recognized in recent years as an opportunistic pathogen causing infections, especially in immunocompromised patients[1]. The article describes the case of a 75-year-old man with severe pneumonia and multiple comorbidities, in whom Cupriavidus gilardii was identified in both bronchoalveolar lavage fluid and sputum cultures[2]. Clinical management of this infection has been challenging as conventional antimicrobial susceptibility testing for this rare isolate has not been possible[2]. The initial empiric treatment consisted of meropenem combined with amphotericin B-cholesteryl sulfate, later the regimen was modified to cefoperazone-sulbactam in combination with minocycline[2]. Targeted therapy resulted in significant improvement in inflammatory markers and chest imaging, but the patient was transferred to a local hospital before complete recovery could be achieved[2]. The case demonstrates that Cupriavidus gilardii can cause severe, life-threatening pneumonia in critically ill patients with multiple comorbidities[2]. The absence of standardized antimicrobial susceptibility testing has necessitated a literature-guided multidisciplinary therapeutic approach[2].